[HTML][HTML] Cancer nanomedicine: progress, challenges and opportunities
J Shi, PW Kantoff, R Wooster, OC Farokhzad - Nature reviews cancer, 2017 - nature.com
The intrinsic limits of conventional cancer therapies prompted the development and
application of various nanotechnologies for more effective and safer cancer treatment …
application of various nanotechnologies for more effective and safer cancer treatment …
Adverse effects of androgen deprivation therapy and strategies to mitigate them
PL Nguyen, SMH Alibhai, S Basaria, AV D'Amico… - European urology, 2015 - Elsevier
Context Androgen-deprivation therapy (ADT) is a key component of treatment for aggressive
and advanced prostate cancer, but it has also been associated with adverse effects on bone …
and advanced prostate cancer, but it has also been associated with adverse effects on bone …
TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?
TMPRSS2 is both the most frequently altered gene in primary prostate cancer and a critical
factor enabling cellular infection by coronaviruses, including SARS-CoV-2. The modulation …
factor enabling cellular infection by coronaviruses, including SARS-CoV-2. The modulation …
[HTML][HTML] Sipuleucel-T immunotherapy for castration-resistant prostate cancer
PW Kantoff, CS Higano, ND Shore… - … England Journal of …, 2010 - Mass Medical Soc
Background Sipuleucel-T, an autologous active cellular immunotherapy, has shown
evidence of efficacy in reducing the risk of death among men with metastatic castration …
evidence of efficacy in reducing the risk of death among men with metastatic castration …
[PDF][PDF] Gene expression correlates of clinical prostate cancer behavior
Prostate tumors are among the most heterogeneous of cancers, both histologically and
clinically. Microarray expression analysis was used to determine whether global biological …
clinically. Microarray expression analysis was used to determine whether global biological …
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Prostate cancer is the second most common cancer in men worldwide and causes over
250,000 deaths each year. Overtreatment of indolent disease also results in significant …
250,000 deaths each year. Overtreatment of indolent disease also results in significant …
[HTML][HTML] Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate …
PW Kantoff, TJ Schuetz, BA Blumenstein… - Journal of Clinical …, 2010 - ncbi.nlm.nih.gov
Purpose Therapeutic prostate-specific antigen (PSA)–targeted poxviral vaccines for prostate
cancer have been well tolerated. PROSTVAC-VF treatment was evaluated for safety and for …
cancer have been well tolerated. PROSTVAC-VF treatment was evaluated for safety and for …
[HTML][HTML] The genomic complexity of primary human prostate cancer
Prostate cancer is the second most common cause of male cancer deaths in the United
States. However, the full range of prostate cancer genomic alterations is incompletely …
States. However, the full range of prostate cancer genomic alterations is incompletely …
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
OC Farokhzad, J Cheng, BA Teply… - Proceedings of the …, 2006 - National Acad Sciences
Targeted uptake of therapeutic nanoparticles in a cell-, tissue-, or disease-specific manner
represents a potentially powerful technology. Using prostate cancer as a model, we report …
represents a potentially powerful technology. Using prostate cancer as a model, we report …
[HTML][HTML] Inherited DNA-repair gene mutations in men with metastatic prostate cancer
Background Inherited mutations in DNA-repair genes such as BRCA2 are associated with
increased risks of lethal prostate cancer. Although the prevalence of germline mutations in …
increased risks of lethal prostate cancer. Although the prevalence of germline mutations in …